Abstract
OAB-041: Daratumumab carfilzomib lenalidomide and dexamethasone as induction therapy in high-risk transplant eligible newly diagnosed myeloma patients: results of the phase 2 study IFM 2018-04
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have